Pulmonology

Dallas Law Firm Chamblee Ryan Promotes Attorneys Reagan Boyce, Annik Morgan to Partner

Retrieved on: 
Tuesday, January 3, 2023
Pulmonology, United States Court of Appeals for the Fifth Circuit, Dog, Intellectual property, Southern University Law Center, Trustee, Lawyer, Insurance, New Leaders Council, Practitioner, Bankruptcy, Private law, Loyola Marymount University, Mentorship, Loyola University, Cardiology, Cancer, Hospital, Volunteering, Dallas Independent School District, Management, Pharmaceutical industry, Southwestern Law School

DALLAS, Jan. 3, 2023 /PRNewswire/ -- The Dallas-based trial law firm of Chamblee Ryan PC is pleased to announce that Reagan E. Boyce and Annik L. Morgan have been named partners.

Key Points: 
  • DALLAS, Jan. 3, 2023 /PRNewswire/ -- The Dallas-based trial law firm of Chamblee Ryan PC is pleased to announce that Reagan E. Boyce and Annik L. Morgan have been named partners.
  • "It's very gratifying to acknowledge the leadership, tenacity, trial skills and commitment to client service that Reagan and Annik have exemplified during the past several years with us," says William H. Chamblee , co-founder and managing partner of the 25-year-old firm.
  • "I'm confident that Reagan and Annik will continue to serve as valuable supporters and mentors for our entire team."
  • Chamblee Ryan PC is a Dallas-based trial firm representing insurance companies, medical professionals, transportation providers, health care institutions and other businesses.

Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029

Retrieved on: 
Thursday, December 22, 2022
Merck KGaA v. Integra Lifesciences I, Ltd., Johnson & Johnson, General surgery, Gel, SAH, Adhesive, Ethicon Inc., Baxter International, Medtronic, Bleeding, Urology, Hospital, Health, Ageing, Infection, Geography, Fibrin, Speciality chemicals, Hemostasis, Orthopedic surgery, Pulmonology, Others, Gynaecology, Teleflex, CryoLife, Neurosurgery

View original content:https://www.prnewswire.com/news-releases/surgical-sealants-adhesives-and...

Key Points: 
  • According to IQ4I analysis, the SAH global market is expected to grow at mid-single digit CAGR from 2022 to 2029 to reach $4,366.0 million by 2029.
  • The SAH global market is mainly segmented based on products, applications, end-users, and based on geography.
  • Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.
  • Hemostats are classified based on function into mechanical hemostats, active hemostats, flowable hemostats, and fibrin sealants hemostats, among them, the mechanical hemostats accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029.

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Retrieved on: 
Tuesday, December 20, 2022
Dark Enlightenment, Maple syrup urine disease, SA, Security (finance), Neurological disorder, UCD School of Medicine, Patient, Liu v. Securities and Exchange Commission, Food, SIX Swiss Exchange, Suicide, Depression, Patent, COVID-19, RLF, FDA, MSUD, PTSD, Phenylketonuria, LR, PKU, Ketamine, Breakthrough, FDA Special Protocol Assessment, Epidermolysis bullosa, EB, Food and Drug Administration Safety and Innovation Act, OTCQB, Therapy, Metabolism, Post-traumatic stress disorder, Database, Connective tissue, Acer, Aviptadil, Pulmonology, Hypochlorous acid, NMDA, Pharmaceutical industry, Relief

GENEVA and RADNOR, Pa., Dec. 20, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals' wholly owned subsidiary, NeuroRx, Inc (NeuroRx). Per the terms of the settlement, (i) NeuroRx has transferred to Relief all of the assets it used in the NRx aviptadil development program, including the regulatory filings, patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief now has the exclusive right and control going forward and the obligation to use commercially reasonable efforts to develop and commercialize an aviptadil product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in the U.S. for at least two years, (iv) Relief will pay NeuroRx milestone payments if it can successfully obtain commercial approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NeuroRx royalties based on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million in the aggregate, (vi) NRx and NeuroRx have agreed not to compete in the development of an aviptadil product in the future, and (vii) Relief and NeuroRx have dismissed their pending litigation.

Key Points: 
  • 53 LR
    GENEVA and RADNOR, Pa., Dec. 20, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals' wholly owned subsidiary, NeuroRx, Inc (NeuroRx).
  • Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc.
  • RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.
  • Relief and NRx do not undertake any obligation to update the information contained herein, which speaks only as of this date.

Relief Therapeutics to Participate in January Investor Meetings

Retrieved on: 
Sunday, December 18, 2022
Epidermolysis bullosa, Maple syrup urine disease, Pulmonology, PKU, FDA, Urea, SIX Swiss Exchange, Phenylketonuria, Hypochlorous acid, Acer, OTCQB, RLF, Orphan, Patent, Therapy, Connective tissue, Metabolism, Pharmaceutical industry, Relief

Jack Weinstein, chief executive officer, will host 1 x 1 institutional investor meetings.

Key Points: 
  • Jack Weinstein, chief executive officer, will host 1 x 1 institutional investor meetings.
  • Jack Weinstein, chief executive officer, will provide an overview of Relief, its rare disease portfolio and efficient commercial footprint.
  • Mr. Weinstein will also host 1 x 1 institutional investor meetings.
  • RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTD.

Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

Retrieved on: 
Tuesday, December 13, 2022
Associate, Neoplasm, Annual report, Security (finance), Atmosphere of Earth, Nitric oxide, MD, Toxicity, COVID-19, Policy, Wilms' tumor, Urinary tract infection, Div, Abscopal effect, Respiratory distress syndrome, Pulmonology, FDA, Safety, Cancer, Stanford University School of Medicine, Radiation, Manuscript, NO, Pulmonary hypertension, NTM, GNO, Kaplan–Meier estimator, Nontuberculous mycobacteria, Surgical oncology, UNO, Patient, Immunotherapy, CCI, APC, Hypoxemia, Death, Ultra, Mouse, B cell, Survival, Metastasis, Pharmaceutical industry, Vaccine, Medical imaging, Surgery

The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).

Key Points: 
  • The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).
  • “Beyond Cancer’s novel implementation of ultra-high concentrations of nitric oxide to treat solid tumors has repeatedly resulted in data demonstrating an immunostimulatory response,” stated Dr. Hila Confino, Chief Scientific Officer.
  • Two weeks post gas treatment, the tumors were resected and a week later a secondary tumor was induced in the contralateral flank.
  • In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models.

Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole

Retrieved on: 
Tuesday, December 6, 2022
Incidence, Aspergillosis, Chronic pulmonary aspergillosis, Cystic fibrosis, IP Group, Lung, Allergic bronchopulmonary aspergillosis, Immunodeficiency, IPA, Pulmonology, Biotechnology, Cystic Fibrosis Foundation, Asthma, Mortality, Critical care, Chronic obstructive pulmonary disease, USD, Patient, United, Vivo, Oxygen toxicity, EUR, Azole, Disease, CHF, Risk, Partnership, Pictet, Pharmaceutical industry, Aspergillus, Pulmocide

Proceeds from the financing will be used to further fund clinical development, manufacturing scale-up, and preparation for potential commercialization of opelconazole.

Key Points: 
  • Proceeds from the financing will be used to further fund clinical development, manufacturing scale-up, and preparation for potential commercialization of opelconazole.
  • Opelconazole is a potent, novel triazole antifungal that has been specifically designed for use as an inhaled therapy against pulmonary aspergillosis.
  • The Company is also conducting a Phase 2b clinical trial using opelconazole as a monotherapy for prophylaxis against aspergillus infections in patients following lung transplant surgery.
  • Under the United Kingdom’s Special Needs provision, opelconazole was found to be generally well tolerated and demonstrated remarkable clinical responses.

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Retrieved on: 
Tuesday, December 6, 2022
Asthma, Private equity, Pulmonology, United, Triazole, Mortality, Cystic fibrosis, Incidence, Series, Aspergillosis, Do Meu Jeito, Oxygen toxicity, Chronic pulmonary aspergillosis, Doctor of Philosophy, Critical care, Cystic Fibrosis Foundation, MD, Azole, Chronic obstructive pulmonary disease, Disease, Immunodeficiency, IP Group, Lung, Allergic bronchopulmonary aspergillosis, Growth, IPA, Investment, Risk, Respiratory disease, Patient, Pharmaceutical industry, Pulmocide, Aspergillus

Jeito previously led an oversubscribed $92 million raise in Pulmocide, and has since provided continuous support to the Company in line with its unique investment strategy.

Key Points: 
  • Jeito previously led an oversubscribed $92 million raise in Pulmocide, and has since provided continuous support to the Company in line with its unique investment strategy.
  • Jeito’s further investment in Pulmocide demonstrates our commitment to support the most innovative biopharmaceutical companies and accelerate the development of much-needed treatments for patients.
  • Jeito Capital has €534 million under management and a rapidly growing portfolio of investments.
  • A late-stage clinical program has been initiated to support registration in patients who have failed prior therapy for IPA.

Global Tobacco Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
Tobacco, Retail, Pulmonology, Solanaceae, Smoking, Degenerative disease, Tobacco, Education, Heart rate, Growth, Blood pressure, Investment, Research, Cancer, COVID-19, Nicotine

Tobacco products are prepared by curing the leaves of tobacco plant which is a part of the genus Nicotiana of the Solanaceae family.

Key Points: 
  • Tobacco products are prepared by curing the leaves of tobacco plant which is a part of the genus Nicotiana of the Solanaceae family.
  • There are more than 70 species of tobacco known till now, however, N. tabacum remains the chief commercial crop.
  • Dried tobacco leaves are majorly used for smoking in cigarettes, cigars, pipes and shisha; and as chewing tobacco, snuff, snus and dipping tobacco.
  • The publisher provides an analysis of the key trends in each sub-segment of the global tobacco market, along with forecasts at the global and regional level from 2022-2027.

OmniSpirant and EVerZom Team up to Develop a New Gene Therapy Treatment for Lung Cancer With Extracellular Vesicles

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Biotechnology, B cell, Therapy, Seminal vesicles, EVS, INSPIRE, Trinity College, Health policy, Lung, Lung cancer, Pulmonology, Trinity College Dublin, Multimedia, AATD, DKFZ, RNA, Cystic fibrosis, Pharmaceutical industry, Cancer

OmniSpirant Limited and EVerZom are delighted to announce the launch of INSPIRE, a 12.8 million lung cancer project funded by Horizon Europe.

Key Points: 
  • OmniSpirant Limited and EVerZom are delighted to announce the launch of INSPIRE, a 12.8 million lung cancer project funded by Horizon Europe.
  • Over the next 3 years of the project, this world-class consortium will progress the development of a regenerative gene therapy as a transformative new treatment for lung cancer.
  • The INSPIRE programme aims to make an important and tangible impact on Europes Beating Cancer Plan and the EU Mission on Cancer.
  • The overall 5-year survival rates for people with lung cancer remain extremely poor, highlighting the desperate need for innovative treatments.

SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis

Retrieved on: 
Wednesday, December 14, 2022
Inhalation, Breathe Me, Eleazar Sukenik, Idiopathic pulmonary fibrosis, Cystic fibrosis, CFTR, Doctor of Philosophy, IPF, Urinary tract infection, Patient, Research, Hebrew University of Jerusalem, Pulmonology, Disease, ASO, Cystic Fibrosis Foundation, RNA transfection, Safety, Asos, Tissue, Life expectancy, Pharmacokinetics, RNA, Mutation, Pharmaceutical industry, Vaccine

The Phase 1/2 placebo-controlled, doubleblind, randomized study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SPL84 consists of two parts.

Key Points: 
  • The Phase 1/2 placebo-controlled, doubleblind, randomized study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SPL84 consists of two parts.
  • "CF is a debilitating disease, leading to frequent lung infections, breathing difficulties and reduced life expectancy," said Gili Hart, PhD, Chief Executive Officer, SpliSense.
  • The Company's pioneering platform harnesses ASOs for treatment of unmet cystic fibrosis mutations and large pulmonary diseases including muco-obstructive diseases and IPF.
  • Investors in the Company include Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation.